Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 3, 2005, Pages 311-315

  Parés, Albert ^a,b   Guañabens, Nuria ^a   Rodés, Juan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Bone turnover; Cholestasis bone disease; IDIBAPS

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 1ALPHA1; GENE PRODUCT; SOMATOMEDIN C; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

BONE DENSITY; BONE TURNOVER; CHOLESTASIS; COLIA1 GENE; DISEASE SEVERITY; EARLY DIAGNOSIS; GENE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MENOPAUSE; METABOLIC BONE DISEASE; OSSIFICATION; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PREDICTION AND FORECASTING; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VITAMIN D RECEPTOR GENE;

BONE DENSITY; BONE RESORPTION; CHOLESTASIS; HUMANS; LIVER CIRRHOSIS, BILIARY; OSTEOGENESIS; OSTEOPOROSIS; POLYMORPHISM, GENETIC;

EID: 15744364688     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200503000-00009     Document Type: Review

References (46)

1. Guañabens N, Parés A, Mariñoso L, Brancós MA, Piera C, Serrano S, et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990; 85:1356-1362.
2. Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14:296-300.
3. Menon J, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. Hepatology 2001; 35:316-323.
4. Guañabens N, Parés A, Ros I, Caballería L, Pons F, Vidal S, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005 (in press).
5. Atkinson M, Nordin BEC, Sherlock S. Malabsorption and bone disease in prolonged obstructive jaundice. QJM 1956; 99:299-312.
6. Kehayoglou AK, Holdsworth CD, Agnew JE, Whelton MJ, Sherlock S. Bone disease and calcium absorption in primary biliary cirrhosis. Lancet 1968; 1:715-719.
7. Compston JE, Thompson RPH. Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis. Lancet 1977; 1:721-724.
8. Brancós MA, Parés A, Bartrons S, Gómez R, Bruguera M, Rodés J, Rotés-Querol J. Las manifestaciones osteoarticulares en la cirrosis biliar primaria. Rev Esp Reumatol 1979; 6:82-89.
9. Arnaud SB. 25-Hydroxyvitamin D3 treatment of bone disease in primary biliary cirrhosis. Gastroenterology 1982; 83:137-140.
10. Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982; 83:97-102.
11. Cuthbert JA, Pak CYC, Zerwekh JE, Glass KD, Combes B. Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 1984; 4:1-8.
12. Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982; 83:103-108.
13. Hodgson SF, Dickson ER, Wahner HW, Johnson KA, Mann KG, Riggs BL. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985; 103:855-860.
14. Stellon AJ, Webb A, Compston J, Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987; 7:137-142.
15. Mitchison HC, Bassendine MF, Malcolm AJ, Watson AJ, Record CO, James OFW. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: Hepatic improvement but greater bone loss. Hepatology 1989; 10:420-429.
16. Diamond TH. Metabolic bone disease in primary biliary cirrhosis. J Gastroenterol Hepatol 1990; 5:66-81.
17. McCaughan GW, Feller RB. Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig Dis 1994; 12:223-231.
18. Hodgson SF, Dickson ER, Eastell R, Eriksen EF, Bryant SC, Riggs BL. Rates of cancellous bone remodelling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993; 14:819-827.
19. Szalay F, Hegedus D, Lakatos PL, Tornai I, Bajnok E, Dunkel K, Lakatos P. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol 2003; 38:395-400.
20. Parés A, Guañabens N, Alvarez L, Monegal A, Caballería L, Ozalla D, et al. High osteoprotegerin and low RANKL levels in primary biliary cirrhosis. Relationship with the severity of liver disease but not with osteoporosis. Hepatology 2004; 40:463A.
21. Guañabens N, Parés A, Navasa M, Martinez de Osaba MJ, Hernández ME, Muñoz J, Rodés J. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. J Hepatol 1994; 21: 24-28.
22. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998; 28:695-699.
23. Cemborain A, Castilla-Cortazar I, Garcia M, Quiroga J, Muguerza B, Picardi A, et al. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol 1998; 28:122-131.
24. Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995; 95:2581-2586.
25. Guichelaar MMJ, Malinchoc M, Sibonga J, Clarke BL, Hay JE. Bone metabolism in advanced cholestatic liver disease: Analysis by bone histomorphometry. Hepatology 2002; 36:895-903.
26. Newton J, Francis R, Prince M, James O, Bassendine M, Rawlings D, Jones D. Osteoporosis in primary biliary cirrhosis revisited. Gut 2001; 49:282-287.
27. Parés A, Guañabens N, Alvarez L, Martinez de Osaba MJ, Oriola J, Pons F, et al. Collagen type I alpha 1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 2001; 33:554-560.
28. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Ebert S. Genetic determinants of bone mass in adults: A twin study. J Clin Invest 1987; 80:706-710.
29. Seeman E, Hopper JL, Bach LA, Cooper ME, Parkinson E, Mckay J, Jeruns G. Reduced bone mass in daughters of women with osteoporosis. N Engl J Med 1989; 320:554-558.
30. Morrison NA, Cheng J, Tokita A, Kelly PJ, Crofts L, Nguyen TV, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367:284-287.
31. Riggs BL, Nguyen TV, Melton III LJ, Morrison NA, O'Fallon WM, Kelly PJ, et al. The contribution of vitamin D receptor gene alleles to the determination of bone mineral density in normal and osteoporotic women. J Bone Miner Res 1995; 10:991-996.
32. Uitterlinden AG, Pols HAP, Burger H, Huang Q, Van Daele PLA, Van Duijn CM, et al. A large-scale population-based study of the association of vitamin D receptor gene polmorphisms with bone mineral density. J Bone Miner Res 1996; 11:1241-1248.
33. Sainz J, Van Tornout JM, Lorg ML, Sayre J, Roe TF, Gilsanz V. Vitamin D-receptor gene polymorphisms and bone density in prepuberal American girls of Mexican descent. N Engl J Med 1997; 337:77-82.
34. McClure L, Eccleshall TR, Gross C, Villa ML, Lin N, Ramaswamy V, et al. Vitamin D receptor polymorphisms, bone mineral density, and bone metabolism in postmenopausal Mexican-America women. J Bone Miner Res 1997; 12:234-240.
35. Fleet JC, Harris SS, Wood RJ, Dawson-Hughes B. The BsmI vitamin D receptor restriction fragment length polymorphism (BB) predicts low bone density in premenopausal black and white women. J Bone Miner Res 1995; 10:985-990.
36. Grant SFA, Reid DM, Blake G, Herd R, Fogelman I, Ralston SH. Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type Iα1 gene. Nat Genet 1996; 14: 203-205.
37. Uitterlinden AG, Burger H, Huang Q, Yue F, MacGuigan FEA, Grant SFA, et al. Relation of alleles of the collagen type Iá1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med 1998; 338:1016-1021.
38. Springer JE, Cole DEC, Rubin LA, Cauch-Dudek K, Harewood L, Evroski J, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000; 118:145-151.
39. Lakatos LP, Bajnok E, Hegedus D, Toth T, Lakatos P, Szalay F. Vitamin D receptor Bsm I, estrogen receptor alpha gene FVu and Xba I and IL-1 receptor-antagonist gene VNRT polymorphism and bone mineral density in Hungarian patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2002; 14:733-740.
40. Vogel A, Strassburg GP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis. Hepatology 2002; 35:126-131.
41. Garnero P, Borel O, Sornay-Rendu E, Arlot ME, Delmas PD. Vitamin D receptor gene polymorphisms are not related to bone turnover, rate of bone loss, and bone mass in postmenopausal women: the OFELY study. J Bone Miner Res 1996; 11:827-834.
42. Cooper GS, Umbach DM. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res 1996; 11:1841-1849.
43. Langdahl BL, Ralston SH, Grant SFA, Eriksen EF. An Sp1 binding site polymorphism in the COLIA1 gene predicts osteoporotic fractures in both men and women. J Bone Miner Res 1998; 13:1384-1389.
44. Keen RW, Woodford-Richens KL, Grant SFA, Ralston SH, Lanchbury JS, Spector TD. Association of polymorphism at the type I collagen (COL1 AI) locus with reduced bone mineral density, increased fracture risk, and increased collagen turnover. Arthritis Rheum 1999; 42:285-290.
45. Mann V, Ralston SH. Meta-analysis of COLIA1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture. Bone 2003; 32:711-717.
46. Lakatos PL, Bajnok E, Tornai I, Folhoffer A, Horvath A, Lakatos P, Szalay F. Insulin-like growth factor I (IGF-I) gene microsatellite repeat, collagen type Iα1 gene (COLIA1) Sp1 polymorphism and bone disease in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2004; 16:753-759.